Cargando…
Conversion Surgery for Pancreatic Cancer—The Impact of Neoadjuvant Treatment
Pancreatic ductal adenocarcinoma (PDAC) has still a dismal prognosis, mainly because only 15–20% of all patients present with resectable tumor stages at the time of diagnosis. Due to locally extended tumor growth or distant metastases upfront resection is not reasonable in the majority of patients....
Autores principales: | Klaiber, Ulla, Hackert, Thilo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971165/ https://www.ncbi.nlm.nih.gov/pubmed/31993372 http://dx.doi.org/10.3389/fonc.2019.01501 |
Ejemplares similares
-
Surgery for Pancreatic Cancer after neoadjuvant treatment
por: Hackert, Thilo
Publicado: (2018) -
Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer
por: Hank, Thomas, et al.
Publicado: (2023) -
Neoadjuvant Treatment in Pancreatic Cancer
por: Oba, Atsushi, et al.
Publicado: (2020) -
Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma
por: Xie, Li, et al.
Publicado: (2019) -
Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?
por: Vivarelli, Marco, et al.
Publicado: (2022)